97 related articles for article (PubMed ID: 32441582)
1. Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan.
Inamoto T; Azuma H; Tatsugami K; Oya M; Adachi M; Okayama Y; Sunaya T; Akaza H
Expert Rev Anticancer Ther; 2020 Jul; 20(7):615-623. PubMed ID: 32441582
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
3. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract][Full Text] [Related]
4. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era.
Takayama T; Kubo T; Yamazaki M; Takeshima S; Komatsubara M; Kameda T; Kamei J; Sugihara T; Fujisaki A; Ando S; Kurokawa S; Fujimura T
Jpn J Clin Oncol; 2019 Dec; 49(12):1164-1171. PubMed ID: 31665407
[TBL] [Abstract][Full Text] [Related]
7. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
9. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
11. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Retz M; Bedke J; Bögemann M; Grimm MO; Zimmermann U; Müller L; Leiber C; Teber D; Wirth M; Bolenz C; van Alphen R; De Santis M; Beeker A; Lehmann J; Indorf M; Frank M; Bokemeyer C; Gschwend JE
Eur J Cancer; 2019 Jan; 107():37-45. PubMed ID: 30529901
[TBL] [Abstract][Full Text] [Related]
12. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Gore ME; Jones RJ; Ravaud A; Kuczyk M; Demkow T; Bearz A; Shapiro J; Strauss UP; Porta C
BJU Int; 2017 Jun; 119(6):846-853. PubMed ID: 27981711
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
PLoS One; 2015; 10(8):e0135165. PubMed ID: 26308612
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study.
Wei D; Wu G; Zheng Y; Chen F; Lu J; Wang Y; He D; Wang H; Wang Z; Chen P; Wang Y; Wang Z; Ye Y; Zhu Z; Yuan J
Medicine (Baltimore); 2019 Feb; 98(5):e14237. PubMed ID: 30702581
[TBL] [Abstract][Full Text] [Related]
19. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
